Pre-made Lirentelimab benchmark antibody ( Whole mAb, anti-SIGLEC8/Siglec-8 therapeutic antibody, Anti-SAF2 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-315

Pre-Made Lirentelimab biosimilar, Whole mAb, Anti-SIGLEC8/Siglec-8 Antibody: Anti-SAF2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lirentelimab (sold under the brand name AK002) is a humanized nonfucosylated monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). In a randomized clinical trial, lirentelimab was found to improve eosinophil counts and symptoms in individuals with eosinophilic gastritis and duodenitis. Adverse reactions include infusion reactions, which are mild to moderate and typically occur following the first infusion.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-315-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Lirentelimab biosimilar, Whole mAb, Anti-SIGLEC8/Siglec-8 Antibody: Anti-SAF2 therapeutic antibody
INN Name Lirentelimab
TargetSIGLEC8
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2020
Year Recommendedna
CompaniesAllakos
Conditions Approvedna
Conditions ActiveEosinophilic gastroenteritis;Eosinophilic oesophagitis;Urticari;Atopic dermatitis;Chronic obstructive pulmonary disease
Conditions DiscontinuedConjunctiviti;Fibrosis;Kertoconjunctivitis;Systemic mastocytosis
Development Techna